pharma · Solid Tumors, Colorectal Cancer and Breast Cancer · HER2 Mutant Non-small Cell Lung Cancer · ELVN
Enliven Therapeutics
Enliven Therapeutics patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2019
- Employees
- 75
- Programs
- 6
- Drugs
- 13
- Patents
- 5
Enliven Therapeutics patents
5 pharmaceutical patents indexed for Enliven Therapeutics. 0 expire within 24 months.
Enliven Therapeutics has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
granted -
US 11807638
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11767321
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
granted -
US 10888597
Composition for treating brain stroke
granted
Frequently asked questions
How many patents does Enliven Therapeutics have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Enliven Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.